nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.08.2012

Proteomics and Systems Biology for Understanding Diabetic Nephropathy

verfasst von: Jonathan M. Starkey, Ronald G. Tilton

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Like many diseases, diabetic nephropathy is defined in a histopathological context and studied using reductionist approaches that attempt to ameliorate structural changes. Novel technologies in mass spectrometry-based proteomics have the ability to provide a deeper understanding of the disease beyond classical histopathology, redefine the characteristics of the disease state, and identify novel approaches to reduce renal failure. The goal is to translate these new definitions into improved patient outcomes through diagnostic, prognostic, and therapeutic tools. Here, we review progress made in studying the proteomics of diabetic nephropathy and provide an introduction to the informatics tools used in the analysis of systems biology data, while pointing out statistical issues for consideration. Novel bioinformatics methods may increase biomarker identification, and other tools, including selective reaction monitoring, may hasten clinical validation.

The Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329, 977–986.

Welsh, G. I., Hale, L. J., Eremina, V., Jeansson, M., Maezawa, Y., Lennon, R., et al. (2010). Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metabolism, 12, 329–340.PubMed

Oates, P. J., & Mylari, B. L. (1999). Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opinion on Investigational Drugs, 8, 2095–2119.PubMed

Brownlee, M., Cerami, A., & Vlassara, H. (1988). Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes/Metabolism Reviews, 4, 437–451.PubMed

Bucala, R., & Vlassara, H. (1995). Advanced glycosylation end products in diabetic renal and vascular disease. American Journal of Kidney Diseases, 26, 875–888.PubMed

Singh, R., Barden, A., Mori, T., & Beilin, L. (2001). Advanced glycation end-products: a review. Diabetologia, 44, 129–146.PubMed

Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. Journal of Clinical Investigation, 96, 1395–1403.PubMed

Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P. M., Chen, J., et al. (2001). Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes, 50, 2792–2808.PubMed

Craven, P. A., Studer, R. K., Negrete, H., & DeRubertis, F. R. (1995). Protein kinase C in diabetic nephropathy. Journal of Diabetes and its Complications, 9, 241–245.PubMed

10.

DeRubertis, F. R., & Craven, P. A. (1994). Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes, 43, 1–8.PubMed

11.

Koya, D., & King, G. L. (1998). Protein kinase C activation and the development of diabetic complications. Diabetes, 47, 859–866.PubMed

12.

Baynes, J. W., & Thorpe, S. R. (1999). Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes, 48, 1–9.PubMed

13.

Szabo, C. (2005). Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacological Research, 52, 60–71.PubMed

14.

Harding, H. P., & Ron, D. (2002). Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes, 51(Suppl 3), S455–S461.PubMed

15.

Araki, E., Oyadomari, S., & Mori, M. (2003). Endoplasmic reticulum stress and diabetes mellitus. Internal Medicine, 42, 7–14.PubMed

16.

Wolf, G. (1998). Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrology, Dialysis, Transplantation, 13, 1131–1142.PubMed

17.

Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S., Matsumura, T., Kaneda, Y., et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404, 787–790.PubMed

18.

Hammes, H. P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., et al. (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine, 9, 294–299.PubMed

19.

Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y., Kawamura, T., et al. (1993). Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 42, 801–813.PubMed

20.

Aebersold, R., & Mann, M. (2003). Mass spectrometry-based proteomics. Nature, 422, 198–207.PubMed

21.

Domon, B., & Aebersold, R. (2006). Mass spectrometry and protein analysis. Science, 312, 212–217.PubMed

22.

Cox, J., & Mann, M. (2011). Quantitative, high-resolution proteomics for data-driven systems biology. Annual Review of Biochemistry, 80, 273–299.PubMed

23.

Schordan, S., Schordan, E., Endlich, N., Lindenmeyer, M. T., Meyer-Schwesinger, C., Meyer, T. N., et al. (2009). Alterations of the podocyte proteome in response to high glucose concentrations. Proteomics, 9, 4519–4528.PubMed

24.

Li, Z., Zhang, H., Dong, X., Burczynski, F. J., Choy, P., Yang, F., et al. (2010). Proteomic profile of primary isolated rat mesangial cells in high-glucose culture condition and decreased expression of PSMA6 in renal cortex of diabetic rats. Biochemical Cell Biology, 88, 635–648.

25.

Tilton, R. G., Haidacher, S. J., LeJeune, W. S., Zhao, Y., Kurosky, A., Brasier, A. R., et al. (2007). Diabetes-induced changes in the renal cortical proteome assessed with two-dimensional gel electrophoresis and mass spectrometry. Proteomics, 7, 1729–1742.PubMed

26.

Zhang, D., Yang, H., Kong, X., Wang, K., Mao, X., Yan, X., et al. (2011). Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes. American Journal of Physiology. Endocrinology and Metabolism, 300, E287–E295.PubMed

27.

Thongboonkerd, V., Barati, M. T., McLeish, K. R., Benarafa, C., Remold-O'Donnell, E., Zheng, S., et al. (2004). Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. Journal of the American Society of Nephrology, 15, 650–662.PubMed

28.

Miyamoto, M., Yoshida, Y., Taguchi, I., Nagasaka, Y., Tasaki, M., Zhang, Y., et al. (2007). In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein prefractionation in combination with liquid chromatography-tandem mass spectrometry. Journal of Proteome Research, 6, 3680–3690.PubMed

29.

Almeida, J. S., Stanislaus, R., Krug, E., & Arthur, J. M. (2005). Normalization and analysis of residual variation in two-dimensional gel electrophoresis for quantitative differential proteomics. Proteomics, 5, 1242–1249.PubMed

30.

Merril, C. R., Creed, G. J., Joy, J., & Olson, A. D. (1993). Identification and use of constitutive proteins for the normalization of high resolution electrophoretograms. Applied and Theoretical Electrophoresis, 3, 329–333.PubMed

31.

Nishihara, J. C., & Champion, K. M. (2002). Quantitative evaluation of proteins in one- and two-dimensional polyacrylamide gels using a fluorescent stain. Electrophoresis, 23, 2203–2215.PubMed

32.

Molloy, M. P., Herbert, B. R., Walsh, B. J., Tyler, M. I., Traini, M., Sanchez, J. C., et al. (1998). Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis, 19, 837–844.PubMed

33.

Marouga, R., David, S., & Hawkins, E. (2005). The development of the DIGE system: 2D fluorescence difference gel analysis technology. Analytical and Bioanalytical Chemistry, 382, 669–678.PubMed

34.

Friedman, D. B., & Lilley, K. S. (2008). Optimizing the difference gel electrophoresis (DIGE) technology. Methods in Molecular Biology, 428, 93–124.PubMed

35.

Tao, W. A., & Aebersold, R. (2003). Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Current Opinion in Biotechnology, 14, 110–118.PubMed

36.

Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology, 17, 994–999.PubMed

37.

Heller, M., Mattou, H., Menzel, C., & Yao, X. (2003). Trypsin catalyzed 16O-to-18O exchange for comparative proteomics: tandem mass spectrometry comparison using MALDI-TOF, ESI-QTOF, and ESI-ion trap mass spectrometers. Journal of the American Society for Mass Spectrometry, 14, 704–718.PubMed

38.

Kostiainen, R., Kotiaho, T., Kuuranne, T., & Auriola, S. (2003). Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. Journal of Mass Spectrometry, 38, 357–372.PubMed

39.

Yost, R. A., & Enke, C. G. (1979). Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation. Analytical Chemistry, 51, 1251–1264.PubMed

40.

Gallien, S., Duriez, E., & Domon, B. (2011). Selected reaction monitoring applied to proteomics. Journal of Mass Spectrometry, 46, 298–312.PubMed

41.

Lange, V., Picotti, P., Domon, B., & Aebersold, R. (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Molecular Systems Biology, 4, 222.PubMed

42.

Cutillas, P. R., Biber, J., Marks, J., Jacob, R., Stieger, B., Cramer, R., et al. (2005). Proteomic analysis of plasma membrane vesicles isolated from the rat renal cortex. Proteomics, 5, 101–112.PubMed

43.

Magni, F., Sarto, C., Valsecchi, C., Casellato, S., Bogetto, S. F., Bosari, S., et al. (2005). Expanding the proteome two-dimensional gel electrophoresis reference map of human renal cortex by peptide mass fingerprinting. Proteomics, 5, 816–825.PubMed

44.

Yoshida, Y., Miyazaki, K., Kamiie, J., Sato, M., Okuizumi, S., Kenmochi, A., et al. (2005). Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup language (XML)-based database. Proteomics, 5, 1083–1096.PubMed

45.

Barile, M., Pisitkun, T., Yu, M. J., Chou, C. L., Verbalis, M. J., Shen, R. F., et al. (2005). Large scale protein identification in intracellular aquaporin-2 vesicles from renal inner medullary collecting duct. Molecular & Cellular Proteomics, 4, 1095–1106.

46.

Dihazi, H., Asif, A. R., Agarwal, N. K., Doncheva, Y., & Muller, G. A. (2005). Proteomic analysis of cellular response to osmotic stress in thick ascending limb of Henle's loop (TALH) cells. Molecular & Cellular Proteomics, 4, 1445–1458.

47.

Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J., Mondal, M., Seonarain, M., et al. (2004). Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics, 4, 1159–1174.PubMed

48.

Oh, J., Pyo, J. H., Jo, E. H., Hwang, S. I., Kang, S. C., Jung, J. H., et al. (2004). Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics, 4, 3485–3497.PubMed

49.

Thongboonkerd, V., McLeish, K. R., Arthur, J. M., & Klein, J. B. (2002). Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney International, 62, 1461–1469.PubMed

50.

Castagna, A., Cecconi, D., Sennels, L., Rappsilber, J., Guerrier, L., Fortis, F., et al. (2005). Exploring the hidden human urinary proteome via ligand library beads. Journal of Proteome Research, 4, 1917–1930.PubMed

51.

Adachi, J., Kumar, C., Zhang, Y., Olsen, J. V., & Mann, M. (2006). The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biology, 7, R80.PubMed

52.

Hewitt, S. M., Dear, J., & Star, R. A. (2004). Discovery of protein biomarkers for renal diseases. Journal of the American Society of Nephrology, 15, 1677–1689.PubMed

53.

He, J. C., Chuang, P. Y., Ma'ayan, A., & Iyengar, R. (2012). Systems biology of kidney diseases. Kidney International, 81, 22–39.PubMed

54.

Barati, M. T., Merchant, M. L., Kain, A. B., Jevans, A. W., McLeish, K. R., & Klein, J. B. (2007). Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. American Journal of Physiology. Renal Physiology, 293, F1157–F1165.PubMed

55.

Thongboonkerd, V., Zheng, S., McLeish, K. R., Epstein, P. N., & Klein, J. B. (2005). Proteomic identification and immunolocalization of increased renal calbindin-D28k expression in OVE26 diabetic mice. The Review of Diabetic Studies, 2, 19–26.PubMed

56.

Cummins, T. D., Barati, M. T., Coventry, S. C., Salyer, S. A., Klein, J. B., & Powell, D. W. (2010). Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling. Biochimica et Biophysica Acta, 1804, 653–661.PubMed

57.

Chougale, A. D., Bhat, S. P., Bhujbal, S. V., Zambare, M. R., Puntambekar, S., Somani, R. S., et al. (2012). Proteomic analysis of glycated proteins from streptozotocin-induced diabetic rat kidney. Molecular Biotechnology, 50, 28–38.PubMed

58.

Sharma, K., Lee, S., Han, S., Lee, S., Francos, B., McCue, P., et al. (2005). Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics, 5, 2648–2655.PubMed

59.

Meier, M., Kaiser, T., Herrmann, A., Knueppel, S., Hillmann, M., Koester, P., et al. (2005). Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. Journal of Diabetes and its Complications, 19, 223–232.PubMed

60.

Dihazi, H., Muller, G. A., Lindner, S., Meyer, M., Asif, A. R., Oellerich, M., et al. (2007). Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clinical Chemistry, 53, 1636–1645.PubMed

61.

Rossing, K., Mischak, H., Rossing, P., Schanstra, J. P., Wiseman, A., & Maahs, D. M. (2008). The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics. Clinical Applications, 2, 997–1007.PubMed

62.

Wolkow, P. P., Niewczas, M. A., Perkins, B., Ficociello, L. H., Lipinski, B., Warram, J. H., et al. (2008). Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. Journal of the American Society of Nephrology, 19, 789–797.PubMed

63.

Otu, H. H., Can, H., Spentzos, D., Nelson, R. G., Hanson, R. L., Looker, H. C., et al. (2007). Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care, 30, 638–643.PubMed

64.

Rao, P. V., Lu, X., Standley, M., Pattee, P., Neelima, G., Girisesh, G., et al. (2007). Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care, 30, 629–637.PubMed

65.

Jiang, H., Guan, G., Zhang, R., Liu, G., Cheng, J., Hou, X., et al. (2009). Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. Diabetes/Metabolism Research and Reviews, 25, 232–241.PubMed

66.

Papale, M., Di, P. S., Magistroni, R., Lamacchia, O., Di Palma, A. M., De, M. A., et al. (2010). Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Diabetes Care, 33, 2409–2415.PubMed

67.

Ben, A. R., Molina, L., Bolvin, C., Kifagi, C., Jarraya, F., Ayadi, H., et al. (2010). Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrology, Dialysis, Transplantation, 25, 2866–2875.

68.

Zhi, W., Purohit, S., Carey, C., Wang, M., & She, J. X. (2010). Proteomic technologies for the discovery of type 1 diabetes biomarkers. Journal of Diabetes Science and Technology, 4, 993–1002.PubMed

69.

Alkhalaf, A., Zurbig, P., Bakker, S. J., Bilo, H. J., Cerna, M., Fischer, C., et al. (2010). Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One, 5, e13421.PubMed

70.

Maahs, D. M., Siwy, J., Argiles, A., Cerna, M., Delles, C., Dominiczak, A. F., et al. (2010). Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One, 5, e13051.PubMed

71.

Parving, H. H., Oxenboll, B., Svendsen, P. A., Christiansen, J. S., & Andersen, A. R. (1982). Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh), 100, 550–555.

72.

Viberti, G. C., Jarrett, R. J., & Keen, H. (1982). Microalbuminuria as prediction of nephropathy in diabetics. Lancet, 2, 611.PubMed

73.

Mogensen, C. E., & Christensen, C. K. (1984). Predicting diabetic nephropathy in insulin-dependent patients. The New England Journal of Medicine, 311, 89–93.PubMed

74.

Mogensen, C. E. (1984). Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. The New England Journal of Medicine, 310, 356–360.PubMed

75.

Weir, M. R., & Bakris, G. L. (2010). Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? American Journal of Nephrology, 31, 469–470.PubMed

76.

Lambers Heerspink, H. J., & de Zeeuw, D. (2010). Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? American Journal of Nephrology, 31, 458–461.PubMed

77.

Glassock, R. J. (2010). Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? American Journal of Nephrology, 31, 462–465.PubMed

78.

Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003). Regression of microalbuminuria in type 1 diabetes. The New England Journal of Medicine, 348, 2285–2293.PubMed

79.

Perkins, B. A., Ficociello, L. H., Ostrander, B. E., Silva, K. H., Weinberg, J., Warram, J. H., et al. (2007). Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. Journal of the American Society of Nephrology, 18, 1353–1361.PubMed

80.

Thongboonkerd, V., Songtawee, N., & Sritippayawan, S. (2007). Urinary proteome profiling using microfluidic technology on a chip. Journal of Proteome Research, 6, 2011–2018.PubMed

81.

Thongboonkerd, V. (2007). Recent progress in urinary proteomics. Proteomics. Clinical Applications, 1, 780–791.PubMed

82.

Coon, J. J., Ueberheide, B., Syka, J. E., Dryhurst, D. D., Ausio, J., Shabanowitz, J., et al. (2005). Protein identification using sequential ion/ion reactions and tandem mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America, 102, 9463–9468.PubMed

83.

Zerefos, P., Prados, J., Kossida, S., Kalousis, A., & Vlahou, A. (2007). Sample preparation and bioinformatics in MALDI profiling of urinary proteins. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 853, 20–30.PubMed

84.

Zerefos, P. G., Vougas, K., Dimitraki, P., Kossida, S., Petrolekas, A., Stravodimos, K., et al. (2006). Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. Proteomics, 6, 4346–4355.PubMed

85.

Kushnir, M. M., Mrozinski, P., Rockwood, A. L., & Crockett, D. K. (2009). A depletion strategy for improved detection of human proteins from urine. Journal of Biomolecular Techniques, 20, 101–108.PubMed

86.

Kolch, W., Neususs, C., Pelzing, M., & Mischak, H. (2005). Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrometry Reviews, 24, 959–977.PubMed

87.

Fliser, D., Novak, J., Thongboonkerd, V., Argiles, A., Jankowski, V., Girolami, M. A., et al. (2007). Advances in urinary proteome analysis and biomarker discovery. Journal of the American Society of Nephrology, 18, 1057–1071.PubMed

88.

Mischak, H., Julian, B. A., & Novak, J. (2007). High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clinical Applications, 1, 792.PubMed

89.

Gilbert, R. E., & Cooper, M. E. (1999). The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney International, 56, 1627–1637.PubMed

90.

Bohle, A., Wehrmann, M., Bogenschutz, O., Batz, C., Muller, C. A., & Muller, G. A. (1991). The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathology, Research and Practice, 187, 251–259.PubMed

91.

Wada, T., Furuichi, K., Sakai, N., Iwata, Y., Yoshimoto, K., Shimizu, M., et al. (2000). Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney International, 58, 1492–1499.PubMed

92.

Merchant, M. L., Perkins, B. A., Boratyn, G. M., Ficociello, L. H., Wilkey, D. W., Barati, M. T., et al. (2009). Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. Journal of the American Society of Nephrology, 20, 2065–2074.PubMed

93.

Bernstam, E. V., Smith, J. W., & Johnson, T. R. (2010). What is biomedical informatics? Journal of Biomedical Informatics, 43, 104–110.PubMed

94.

Nesvizhskii, A. I. (2010). A survey of computational methods and error rate estimation procedures for peptide and protein identification in shotgun proteomics. Journal of Proteomics, 73, 2092–2123.PubMed

95.

Nagaraj, N., & Mann, M. (2011). Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. Journal of Proteome Research, 10, 637–645.PubMed

96.

Hunt, S. M., Thomas, M. R., Sebastian, L. T., Pedersen, S. K., Harcourt, R. L., Sloane, A. J., et al. (2005). Optimal replication and the importance of experimental design for gel-based quantitative proteomics. Journal of Proteome Research, 4, 809–819.PubMed

97.

Levin, Y. (2011). The role of statistical power analysis in quantitative proteomics. Proteomics, 11, 2565–2567.PubMed

98.

Moore, C. G., Carter, R. E., Nietert, P. J., & Stewart, P. W. (2011). Recommendations for planning pilot studies in clinical and translational research. Clinical and Translational Science, 4, 332–337.PubMed

99.

Martens, L., Hermjakob, H., Jones, P., Adamski, M., Taylor, C., States, D., et al. (2005). PRIDE: the proteomics identifications database. Proteomics, 5, 3537–3545.PubMed

100.

Kolker, E., Higdon, R., Haynes, W., Welch, D., Broomall, W., Lancet, D., et al. (2012). MOPED: Model Organism Protein Expression Database. Nucleic Acids Research, 40, D1093–D1099.PubMed

101.

Orchard, S., & Hermjakob, H. (2008). The HUPO proteomics standards initiative–easing communication and minimizing data loss in a changing world. Briefings in Bioinformatics, 9, 166–173.PubMed

102.

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177–188.PubMed

103.

Jorge, I., Navarro, P., Martinez-Acedo, P., Nunez, E., Serrano, H., Alfranca, A., et al. (2009). Statistical model to analyze quantitative proteomics data obtained by 18O/16O labeling and linear ion trap mass spectrometry: application to the study of vascular endothelial growth factor-induced angiogenesis in endothelial cells. Molecular & Cellular Proteomics, 8, 1130–1149.

104.

Bonzon-Kulichenko, E., Martinez-Martinez, S., Trevisan-Herraz, M., Navarro, P., Redondo, J. M., & Vazquez, J. (2011). Quantitative in-depth analysis of the dynamic secretome of activated Jurkat T-cells. Journal of Proteomics, 75, 561–571.PubMed

105.

Fogle, R. L., Hollenbeak, C. S., Stanley, B. A., Vary, T. C., Kimball, S. R., & Lynch, C. J. (2011). Functional proteomic analysis reveals sex-dependent differences in structural and energy-producing myocardial proteins in rat model of alcoholic cardiomyopathy. Physiological Genomics, 43, 346–356.PubMed

106.

Carbon, S., Ireland, A., Mungall, C. J., Shu, S., Marshall, B., & Lewis, S. (2009). AmiGO: online access to ontology and annotation data. Bioinformatics, 25, 288–289.PubMed

107.

Zhao, Y., Denner, L., Haidacher, S. J., LeJeune, W. S., & Tilton, R. G. (2008). Comprehensive analysis of the mouse renal cortex using two-dimensional HPLC - tandem mass spectrometry. Proteome Sci, 6, 15.PubMed

108.

Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research, 28, 27–30.PubMed

109.

Cline, M. S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., et al. (2007). Integration of biological networks and gene expression data using Cytoscape. Nature Protocols, 2, 2366–2382.PubMed

110.

Hu, Z., Hung, J. H., Wang, Y., Chang, Y. C., Huang, C. L., Huyck, M., et al. (2009). VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. Nucleic Acids Research, 37, W115–W121.PubMed

111.

Vidal, M., Cusick, M. E., & Barabasi, A. L. (2011). Interactome networks and human disease. Cell, 144, 986–998.PubMed

112.

Pflieger, D., Gonnet, F., de la Fuente van Bentem, S., Hirt, H., & de la FA, A. (2011). Linking the proteins–elucidation of proteome-scale networks using mass spectrometry. Mass Spectrometry Reviews, 30, 268–297.PubMed

113.

Starkey, J. M., Zhao, Y., Sadygov, R. G., Haidacher, S. J., LeJeune, W. S., Dey, N., et al. (2010). Altered retinoic acid metabolism in diabetic mouse kidney identified by O isotopic labeling and 2D mass spectrometry. PLoS One, 5, e11095.PubMed

114.

Overgaard, A. J., Thingholm, T. E., Larsen, M. R., Tarnow, L., Rossing, P., McGuire, J. N., et al. (2010). Quantitative iTRAQ-based proteomic identification of candidate biomarkers for diabetic nephropathy in plasma of type 1 diabetic patients. Clin Proteomics, 6, 105–114.PubMed

Titel: Proteomics and Systems Biology for Understanding Diabetic Nephropathy
verfasst von: Jonathan M. Starkey
Ronald G. Tilton
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2012
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-012-9372-9

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Erratum to: Cardiovascular Disease Risk in Young People with Type 1 Diabetes

Association Between Endothelial Nitric Oxide Synthase Polymorphisms and Atrial Fibrillation: A Meta-analysis

Diabetic Complications: Current Challenges and Opportunities

MicroRNAs and Diabetic Complications